Postpartum depression linked to atopic dermatitis in children

Publication
Article
Contemporary PEDS JournalVol 37 No 4
Volume 37
Issue 4

Postpartum depression has a number of profound effects. A new study indicates that postpartum depression could increase the risk of atopic dermatitis, especially at ages 5 and 9 years.

Postpartum depression can have a number of profound effects not only on the mother, but for children as well. A new study published in Dermatitis indicates that children with mothers who had postpartum depression may have an increased risk of developing atopic dermatitis (AD).1

The investigators used the Fragile Families and Child Wellbeing Study (FFCWS), which is a prospective cohort study of 4898 children who were born in 20 metropolitan cities in the United States. They found that a history of postpartum depression was linked with childhood AD (multivariable logistic regression; adjusted odds ratio [aOR], 1.32; 95% confidence interval [CI], 1.06-1.64). The association was particularly pronounced in children aged 5 years (aOR, 1.34; 95% CI, 1.04-1.73) and 9 years (aOR, 1.37; 95% CI, 1.10-1.70).

A history of maternal depression increases AD risk

Additionally, postpartum depression was linked to more persistent AD (present at age 2 years: aOR, 1.58; 95% CI, 1.12-2.22; at 3 years: aOR, 1.73; 95% CI, 1.15-2.60). A history of maternal depression in the past year was linked to significantly higher odds of AD in children aged 5 years (aOR, 1.54; 95% CI, 1.20-1.99); 9 years (aOR, 1.36; 95% CI, 1.10-1.71); and 15 years (aOR, 1.43; 95% CI, 1.13-1.80).

Furthermore, mother’s depression was associated with higher odds of AD in offspring during 1 year (aOR, 1.50; 95% CI, 1.16-1.94), 2 years (aOR, 1.60; 95% CI, 1.16-2.19), or all 3 years of interviews (aOR, 1.61; 95% CI, 1.06-2.45).

The researchers concluded that depression in the postpartum period and beyond appears to be linked with AD in both childhood and adolescence.

References:

 

1. McKenzie C, Silverberg J. Maternal depression and atopic dermatitis in American children and adolescents. Dermatitis. 2020;31(1):75-80.

Related Videos
James Wallace, MD | Image Credit: Provided by James Wallace, MD
Image Credit: Marcibowers.com
Benjamin Maxwell, MD, chief of child and adolescent psychiatry, Rady Children’s Hospital, San Diego, California | Image provided
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Thomas R. Young, MD | Image Credit: Author provided
Steven Selbst, MD
Erica Sood, MD | Image Credit: Nemours
© 2023 MJH Life Sciences

All rights reserved.